Skip to Main Content

QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery

Conditions

Diseases of the Cardiovascular System | Diseases of the Kidney & Urinary Tract

Phase III

What is the purpose of this trial?

Brief Summary:

This trial is designed to evaluate QPI-1002 versus placebo for the prevention of Major Adverse Kidney Events (MAKE) in subjects at high risk for acute kidney injury following cardiac surgery. Half of the participants will receive QPI-1002 while the other half will receive placebo.

  • Trial with
    Quark Pharmaceuticals
  • Start Date
    03/03/2019
  • End Date
    07/30/2021
Trial Image

For more information about this study, contact:

Karen Stavris

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    07/15/2019
  • Study HIC
    #2000024823